Skip to main content

Day: July 8, 2021

Windtree to Present at Access to Giving Virtual Investor Conference

WARRINGTON, Pa., July 08, 2021 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present at the Access to Giving Virtual Investor conference, which is being held virtually July 13–15, 2021. Access to Giving is a conference themed around investor education and advocacy with 50+ companies presenting, a keynote, three distinctive panels and 1×1 meetings. Windtree Therapeutics is scheduled to present on Thursday, July 15, 2021 at 10:00 AM Eastern Time. Investors can register here. Management will be available for one-on-one meetings to be held throughout the conference and the presentation...

Continue reading

ProMIS Neurosciences Obtains Receipt for Final Base Shelf Prospectus

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce that it has filed, and obtained a receipt for, a final short form base shelf prospectus (the “Shelf Prospectus”) with the securities regulators in each of the provinces and territories of Canada, except Quebec. The Shelf Prospectus allows the Company to make offerings of common shares, warrants, units, debt securities, subscription...

Continue reading

Gold’n Futures Adds High Priority Gold Targets Within the Expanded Hercules Property in Beardmore-Geraldton Gold Camp, Ontario

Figure-1Regional Target-1 – the North Kaby Lake Stock. Compilation plan of major geological and geophysical features on VLF conductor base map.Figure-2Regional Target-2 – Ballina Lake Gold Zone. Compilation Map on total magnetic Field base map.VANCOUVER, British Columbia, July 08, 2021 (GLOBE NEWSWIRE) — Gold’n Futures Mineral Corp. (the “Company” or “Gold’n Futures”) is pleased to report that the compilation of historical data on the Hercules Gold Property has identified two additional gold targets for its 2021 exploration program associated with indicative geological, geophysical and geochemical anomalies. Significantly, these new targets were found outside of and to the east of the Elmhirst Lake Intrusive Complex that is the host for the high-grade Hercules gold vein systems. “This is...

Continue reading

Helius Medical Technologies, Inc. Appoints Antonella Favit-Van Pelt, M.D., Ph.D. as Chief Medical Officer

NEWTOWN, Pa., July 08, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the appointment of Antonella Favit-Van Pelt, M.D., Ph.D. to the position of Chief Medical Officer. “I am very pleased to welcome Dr. Favit-Van Pelt to Helius, who joins our team with a clinical and academic background in Neurology, as well as 20 years of experience advising and leading medical programs for healthcare companies – including both large, globally-diversified corporations and smaller, earlier-stage companies,” said Helius CEO, Dane Andreeff. “I look forward to her future contributions as we continue our efforts to raise awareness of PoNS technology and its therapeutic benefits among clinicians, patients and payors in...

Continue reading

Nephros Announces Preliminary Results for Second Quarter of 2021

Anticipates Net Revenue of $2.2 Million, Greater Than 40% Year-Over-Year Increase;Submits HDF Product to FDA for 510(k) Clearance SOUTH ORANGE, NJ, July 08, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced preliminary results for the second quarter of 2021. Revenue for the quarter ended June 30, 2021 is expected to be approximately $2.2 million, a year-over-year increase of over 40%. In addition, the Company submitted its HDF Assist Module for FDA 510(k) clearance. “We are very pleased with the results of the second quarter,” said Andy Astor, Chief Executive Officer of Nephros. “Revenue growth seems to be returning to pre-pandemic levels. In addition, revenue...

Continue reading

Kforce Inc. Announces Second Quarter 2021 Earnings Date

TAMPA, Fla., July 08, 2021 (GLOBE NEWSWIRE) — Kforce Inc. (NASDAQ: KFRC), a provider of professional staffing services and solutions, will release second quarter results post-market on Tuesday, August 3, 2021, followed by a conference call at 5:00 pm ET to discuss the results. The dial-in number is (866) 211-4958 and the conference passcode is “Kforce”. A replay of the call will be available at http://investor.kforce.com for one year after the call. About Kforce Inc. Kforce Inc. is a domestic professional staffing services and solutions firm that specializes in the areas of Technology and Finance and Accounting. Each year, through our network of field offices located throughout the U.S. and two national delivery centers, we provide opportunities for over 30,000 highly skilled professionals who work with approximately 3,000 clients,...

Continue reading

Ayr Wellness Adds to its Florida Footprint, Opens New Dispensary in Key West

TORONTO, July 08, 2021 (GLOBE NEWSWIRE) — Ayr Wellness Inc. (CSE: AYR.A, OTC: AYRWF) (“Ayr” or the “Company”), a leading vertically integrated cannabis multi-state operator, announced today the opening of Liberty Health Sciences Key West, the Company’s 37th open dispensary in Florida. The dispensary is located at 826 Duval Street, Key West, Florida, 33040. The 1,500 sq. ft. location sits on the main strip of Downtown Key West, with a diverse selection of restaurants, shops and attractions nearby. The dispensary features a selection of flower products, in addition to the company’s newly launched Origyn concentrates and Big Pete’s Cookies. Jonathan Sandelman, CEO of Ayr, said, “We are continuing to execute on our Florida plan, opening dispensaries in prime locations while continually enhancing our cultivation efforts to make us the...

Continue reading

Aehr Test Systems to Announce Fiscal 2021 Fourth Quarter and Full Year Financial Results on July 15, 2021

FREMONT, Calif., July 08, 2021 (GLOBE NEWSWIRE) — Aehr Test Systems (NASDAQ: AEHR), a worldwide supplier of semiconductor test and reliability qualification equipment, today announced that it will report financial results for its fiscal 2021 fourth quarter and full year ended May 31, 2021 on Thursday, July 15, 2021 following the close of the market. The Company will host a conference call and webcast at 5:00 p.m. Eastern time to discuss the results.What: Aehr Test Systems fourth quarter fiscal 2021 financial results conference call.   When: Thursday, July 15, at 5:00 p.m. Eastern Time (2:00 p.m. PT).   Dial in Number: To access the live call, dial 800-367-2403 (US and Canada) or +1 334-777-6978 (International) and give the participant passcode 9748167.   Webcast:  To access the live webcast, please visit the...

Continue reading

FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials

ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia CAMBRIDGE, Mass. and TOKYO, July 08, 2021 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced the U.S. Food and Drug Administration (FDA) has approved an updated label for ADUHELM™ (aducanumab-avwa) injection 100 mg/mL solution. The update includes an addition to the Indications and Usage section of the label (Section 1) to emphasize the disease stages studied in the clinical trials, as seen below (italics to note updated language). ADUHELM is indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in...

Continue reading

Hanstone Gold Announces Private Placement Financing

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, July 08, 2021 (GLOBE NEWSWIRE) — Hanstone Gold Corp. (TSXV: HANS) (FSE: HGO) (“Hanstone” or the “Company“), announces that it will conduct a non-brokered private placement for aggregate gross proceeds of up to $4,000,000 (the “Offering”), consisting of: (i) units of the Company (the “Units”) at a price of $0.40 per Unit, and (ii) flow-through units of the Company (the “FT Units”) at a price of $0.44 per FT Unit. Each Unit will be comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each FT Unit shall consist of one Common Share of the Company which will qualify as a “flow-through share” (within the meaning of the Income...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.